The stock of BridgeBio Pharma Inc (NASDAQ: BBIO) has decreased by -2.63 when compared to last closing price of 44.86. Despite this, the company has experienced a 3.57% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-30 that PALO ALTO, Calif., June 30, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced it has sold a portion of royalties due to the Company from sales of BEYONTTRA in Europe to HealthCare Royalty (“HCRx”) and funds managed by Blue Owl Capital (“Blue Owl”) for $300 million. This royalty financing agreement monetizes select anticipated royalties and provides immediate less-dilutive capital to the Company.
Is It Worth Investing in BridgeBio Pharma Inc (NASDAQ: BBIO) Right Now?
Company’s 36-month beta value is 1.16.Analysts have differing opinions on the stock, with 11 analysts rating it as a “buy,” 6 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for BBIO is 160.76M, and currently, short sellers hold a 13.14% ratio of that floaft. The average trading volume of BBIO on June 30, 2025 was 3.08M shares.
BBIO’s Market Performance
The stock of BridgeBio Pharma Inc (BBIO) has seen a 3.57% increase in the past week, with a 30.90% rise in the past month, and a 24.41% gain in the past quarter. The volatility ratio for the week is 3.58%, and the volatility levels for the past 30 days are at 4.09% for BBIO. The simple moving average for the last 20 days is 7.43% for BBIO stock, with a simple moving average of 38.76% for the last 200 days.
Analysts’ Opinion of BBIO
Many brokerage firms have already submitted their reports for BBIO stocks, with Wolfe Research repeating the rating for BBIO by listing it as a “Outperform.” The predicted price for BBIO in the upcoming period, according to Wolfe Research is $49 based on the research report published on June 17, 2025 of the current year 2025.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see BBIO reach a price target of $50. The rating they have provided for BBIO stocks is “Buy” according to the report published on March 31st, 2025.
BBIO Trading at 17.45% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.96% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBIO starting from MCCORMICK FRANK, who sale 100,000 shares at the price of $44.23 back on Jun 24 ’25. After this action, MCCORMICK FRANK now owns 879,979 shares of BridgeBio Pharma Inc, valued at $4,422,800 using the latest closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -5.48 for the present operating margin
- 0.97 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -5.24. The total capital return value is set at -0.96.
Based on BridgeBio Pharma Inc (BBIO), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -49.43. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is -5.91.
Currently, EBITDA for the company is -436.83 million with net debt to EBITDA at 0.96. When we switch over and look at the enterprise to sales, we see a ratio of 60.61. The receivables turnover for the company is 1.11for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.57.
Conclusion
In a nutshell, BridgeBio Pharma Inc (BBIO) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
